Compare American Express Co (AXP) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Express Co vs BridgeBio Pharma Inc — how do they compare? American Express Co trades at $341 (market cap $228.84B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: American Express Co is far larger — about 13.8× BridgeBio Pharma Inc's market cap, and American Express Co pays a 1.12% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| AXP | BBIO | |
|---|---|---|
Market Cap | $228.84B | $16.61B |
Sector | Financials | Health |
52-Week High | $384.82 | $90.17 |
52-Week Low | $292.27 | $47.29 |
Dividend Yield | 1.12% | — |
Enterprise Value | — | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Express (AXP) trades at $340.91, down 0.49% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings of $4.53 EPS, beating estimates, and maintains robust fundamentals with 15.07% net income margin and 33.97% ROE. Recent news highlights Amex's focus on premium card member experiences and strategic investments in AI for small businesses.
AXP presents a compelling growth story with consistent revenue expansion and strong profitability, though premium valuation metrics (P/E 20.69, P/B 6.72) warrant caution. Analyst consensus leans bullish with a $369.42 price target, representing 8.4% upside potential. Key risks include competitive pressures in payments and sensitivity to economic cycles affecting consumer spending.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
